MEMPHIS, Tenn.--(BUSINESS WIRE)--GTx, Inc. (NASDAQ: GTXI) announced today that data from a recently conducted Phase II Ostarine™ clinical trial of 60 elderly men and 60 postmenopausal women revealed that insulin and glucose levels were reduced and insulin resistance was improved among subjects receiving the 3 mg dose of Ostarine compared to baseline. These observations were even more pronounced among a subset of prediabetic subjects.
